Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Andrea Rubbert-Roth

Prof Dr

Kantonsspital St. Gallen

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

30%

Internal Medicine

30%

Rheumatology

70%

Anti-inflammatory Research

60%

Targeted Therapy

60%

Inflammatory Disease

40%

Systemic Lupus Erythematosus

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles13

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

Article Link

Year:

2025

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

Article Link

Year:

2024

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Article Link

Year:

2024

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

Article Link

Year:

2024

Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases

Article Link

Year:

2023

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry

Article Link

Year:

2023

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy

Article Link

Year:

2022

Anti-interleukin-23-directed therapy and the recurrence of severe allergic asthma

Article Link

Year:

2022

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

Article Link

Year:

2022

Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis

Article Link

Year:

2021

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis

Article Link

Year:

2021

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.

Article Link

Year:

2020

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Article Link

Year:

2020

Collaborators7

Catherine Elizabeth Raptis

Deputy Head of Science

SWITZERLAND

Daniel Manoil

Karolinska Institutet

SWEDEN

Raphael Micheroli

University Hospital of Zurich

SWITZERLAND

Bernard Combe

Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments

University of Montpellier

FRANCE

Diana Dan

Lausanne University Hospital

SWITZERLAND

Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

Axel Finckh

University Hospital of Geneva

SWITZERLAND

How do I reach out?

Meet Kite AI